Healthcare Intelligence
Ophthalmology & Vision Care
Real-time intelligence, expert analysis, and verified research for the Ophthalmology & Vision Care industry. Stay ahead in 3 minutes a day.
Stay ahead of Ophthalmology & Vision Care in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
Breakthrough Light Therapy Helps New Zealanders Regain Vision
Study shows 59% of dry AMD patients achieved vision improvement with Photobiomodulation therapy, helping maintain driving independence.
Read full articlePulsesight Reports Positive Phase 1 Data for PST-611 in Dry AMD
Non-viral gene therapy shows excellent safety and early efficacy signals in geographic atrophy patients.
Read full articleBayer Acquires Perfuse Therapeutics for $2.45 Billion
Deal includes PER-001, a potential first disease-modifying treatment for glaucoma and diabetic retinopathy.
Read full articleSightGlass DOT Lenses Show 67% Reduction in Myopia Progression
24-month data reveals spectacle lenses saved over 1 diopter of myopic progression in children aged 6-10.
Read full articleMingMed's QA102 Shows Promise for Intermediate AMD Treatment
Phase 2 oral therapy reduced drusen volume growth by 118% and GA progression by 42.7% versus placebo.
Read full articleBreakthrough Light Therapy Helps New Zealanders Regain Vision
Study shows 59% of dry AMD patients achieved vision improvement with Photobiomodulation therapy, helping maintain driving independence.
Read full articlePulsesight Reports Positive Phase 1 Data for PST-611 in Dry AMD
Non-viral gene therapy shows excellent safety and early efficacy signals in geographic atrophy patients.
Read full articleBayer Acquires Perfuse Therapeutics for $2.45 Billion
Deal includes PER-001, a potential first disease-modifying treatment for glaucoma and diabetic retinopathy.
Read full articleSightGlass DOT Lenses Show 67% Reduction in Myopia Progression
24-month data reveals spectacle lenses saved over 1 diopter of myopic progression in children aged 6-10.
Read full articleMingMed's QA102 Shows Promise for Intermediate AMD Treatment
Phase 2 oral therapy reduced drusen volume growth by 118% and GA progression by 42.7% versus placebo.
Read full articleStay ahead of Ophthalmology & Vision Care in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.